Jump to content
RemedySpot.com

Treatment of Chronic Hepatitis C Patients with the NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227) Leads to Robust Reductions in Viral RNA: A Phase 1b Multiple Ascending Dose Study

Rate this topic


Recommended Posts

Posted

J Hepatol. 2010 Dec 8. [Epub ahead of print]

Treatment of Chronic Hepatitis C Patients with the NS3/4A Protease Inhibitor

Danoprevir (ITMN-191/RG7227) Leads to Robust Reductions in Viral RNA: A Phase 1b

Multiple Ascending Dose Study.

Forestier N, Larrey D, Guyader D, Marcellin P, Rouzier R, Patat A, P,

Bradford W, Porter S, Blatt L, Seiwert SD, Zeuzem S.

J.W. Goethe Universität, furt, Germany.

Abstract

Danoprevir is a potent and selective inhibitor of the hepatitis C virus (HCV)

NS3/4A serine protease. The present study assessed the safety, pharmacokinetics

and antiviral activity of danoprevir in a randomized, placebo-controlled, 14-day

multiple ascending dose study in patients with chronic HCV genotype 1 infection.

Four cohorts of treatment-naïve (TN) patients (100 mg q12h, 100 mg q8h, 200 mg

q12h, 200 mg q8h) and one cohort of non-responders (NR) to prior pegylated

interferon alfa-ribavirin treatment (300 mg q12h) were investigated. RESULTS:

Danoprevir was safe and well tolerated; adverse events were generally mild,

transient and without association to treatment group or dose level. Danoprevir

displayed a slightly more than proportional increase in exposure with increasing

daily dose and was rapidly eliminated from the plasma compartment. Maximal

decreases in HCV RNA were -3.9 log(10) IU/mL and -3.2 log(10) IU/mL in TN

receiving 200 mg q8h and 200 mg q12h, respectively. End of treatment viral

decline in these two cohorts was within 0.1 log(10) IU/mL of viral load nadir.

HCV RNA reduction in NR was more modest than that observed in upper dose TN

cohorts. The overall incidence of viral rebound was low (10/37) and was

associated with R155K substitution in NS3 regardless of HCV subtype. CONCLUSION:

Danoprevir was safe and well tolerated when administered for 14 days in patients

with chronic HCV genotype 1 infection. Treatment resulted in sustained,

multi-log(10) IU/mL reductions in HCV RNA in upper dose cohorts. These results

support further clinical evaluation of danoprevir in patients with chronic HCV.

. Published by Elsevier B.V.

PMID: 21145848 [PubMed - as supplied by publisher]

Posted

J Hepatol. 2010 Dec 8. [Epub ahead of print]

Treatment of Chronic Hepatitis C Patients with the NS3/4A Protease Inhibitor

Danoprevir (ITMN-191/RG7227) Leads to Robust Reductions in Viral RNA: A Phase 1b

Multiple Ascending Dose Study.

Forestier N, Larrey D, Guyader D, Marcellin P, Rouzier R, Patat A, P,

Bradford W, Porter S, Blatt L, Seiwert SD, Zeuzem S.

J.W. Goethe Universität, furt, Germany.

Abstract

Danoprevir is a potent and selective inhibitor of the hepatitis C virus (HCV)

NS3/4A serine protease. The present study assessed the safety, pharmacokinetics

and antiviral activity of danoprevir in a randomized, placebo-controlled, 14-day

multiple ascending dose study in patients with chronic HCV genotype 1 infection.

Four cohorts of treatment-naïve (TN) patients (100 mg q12h, 100 mg q8h, 200 mg

q12h, 200 mg q8h) and one cohort of non-responders (NR) to prior pegylated

interferon alfa-ribavirin treatment (300 mg q12h) were investigated. RESULTS:

Danoprevir was safe and well tolerated; adverse events were generally mild,

transient and without association to treatment group or dose level. Danoprevir

displayed a slightly more than proportional increase in exposure with increasing

daily dose and was rapidly eliminated from the plasma compartment. Maximal

decreases in HCV RNA were -3.9 log(10) IU/mL and -3.2 log(10) IU/mL in TN

receiving 200 mg q8h and 200 mg q12h, respectively. End of treatment viral

decline in these two cohorts was within 0.1 log(10) IU/mL of viral load nadir.

HCV RNA reduction in NR was more modest than that observed in upper dose TN

cohorts. The overall incidence of viral rebound was low (10/37) and was

associated with R155K substitution in NS3 regardless of HCV subtype. CONCLUSION:

Danoprevir was safe and well tolerated when administered for 14 days in patients

with chronic HCV genotype 1 infection. Treatment resulted in sustained,

multi-log(10) IU/mL reductions in HCV RNA in upper dose cohorts. These results

support further clinical evaluation of danoprevir in patients with chronic HCV.

. Published by Elsevier B.V.

PMID: 21145848 [PubMed - as supplied by publisher]

Posted

J Hepatol. 2010 Dec 8. [Epub ahead of print]

Treatment of Chronic Hepatitis C Patients with the NS3/4A Protease Inhibitor

Danoprevir (ITMN-191/RG7227) Leads to Robust Reductions in Viral RNA: A Phase 1b

Multiple Ascending Dose Study.

Forestier N, Larrey D, Guyader D, Marcellin P, Rouzier R, Patat A, P,

Bradford W, Porter S, Blatt L, Seiwert SD, Zeuzem S.

J.W. Goethe Universität, furt, Germany.

Abstract

Danoprevir is a potent and selective inhibitor of the hepatitis C virus (HCV)

NS3/4A serine protease. The present study assessed the safety, pharmacokinetics

and antiviral activity of danoprevir in a randomized, placebo-controlled, 14-day

multiple ascending dose study in patients with chronic HCV genotype 1 infection.

Four cohorts of treatment-naïve (TN) patients (100 mg q12h, 100 mg q8h, 200 mg

q12h, 200 mg q8h) and one cohort of non-responders (NR) to prior pegylated

interferon alfa-ribavirin treatment (300 mg q12h) were investigated. RESULTS:

Danoprevir was safe and well tolerated; adverse events were generally mild,

transient and without association to treatment group or dose level. Danoprevir

displayed a slightly more than proportional increase in exposure with increasing

daily dose and was rapidly eliminated from the plasma compartment. Maximal

decreases in HCV RNA were -3.9 log(10) IU/mL and -3.2 log(10) IU/mL in TN

receiving 200 mg q8h and 200 mg q12h, respectively. End of treatment viral

decline in these two cohorts was within 0.1 log(10) IU/mL of viral load nadir.

HCV RNA reduction in NR was more modest than that observed in upper dose TN

cohorts. The overall incidence of viral rebound was low (10/37) and was

associated with R155K substitution in NS3 regardless of HCV subtype. CONCLUSION:

Danoprevir was safe and well tolerated when administered for 14 days in patients

with chronic HCV genotype 1 infection. Treatment resulted in sustained,

multi-log(10) IU/mL reductions in HCV RNA in upper dose cohorts. These results

support further clinical evaluation of danoprevir in patients with chronic HCV.

. Published by Elsevier B.V.

PMID: 21145848 [PubMed - as supplied by publisher]

Posted

J Hepatol. 2010 Dec 8. [Epub ahead of print]

Treatment of Chronic Hepatitis C Patients with the NS3/4A Protease Inhibitor

Danoprevir (ITMN-191/RG7227) Leads to Robust Reductions in Viral RNA: A Phase 1b

Multiple Ascending Dose Study.

Forestier N, Larrey D, Guyader D, Marcellin P, Rouzier R, Patat A, P,

Bradford W, Porter S, Blatt L, Seiwert SD, Zeuzem S.

J.W. Goethe Universität, furt, Germany.

Abstract

Danoprevir is a potent and selective inhibitor of the hepatitis C virus (HCV)

NS3/4A serine protease. The present study assessed the safety, pharmacokinetics

and antiviral activity of danoprevir in a randomized, placebo-controlled, 14-day

multiple ascending dose study in patients with chronic HCV genotype 1 infection.

Four cohorts of treatment-naïve (TN) patients (100 mg q12h, 100 mg q8h, 200 mg

q12h, 200 mg q8h) and one cohort of non-responders (NR) to prior pegylated

interferon alfa-ribavirin treatment (300 mg q12h) were investigated. RESULTS:

Danoprevir was safe and well tolerated; adverse events were generally mild,

transient and without association to treatment group or dose level. Danoprevir

displayed a slightly more than proportional increase in exposure with increasing

daily dose and was rapidly eliminated from the plasma compartment. Maximal

decreases in HCV RNA were -3.9 log(10) IU/mL and -3.2 log(10) IU/mL in TN

receiving 200 mg q8h and 200 mg q12h, respectively. End of treatment viral

decline in these two cohorts was within 0.1 log(10) IU/mL of viral load nadir.

HCV RNA reduction in NR was more modest than that observed in upper dose TN

cohorts. The overall incidence of viral rebound was low (10/37) and was

associated with R155K substitution in NS3 regardless of HCV subtype. CONCLUSION:

Danoprevir was safe and well tolerated when administered for 14 days in patients

with chronic HCV genotype 1 infection. Treatment resulted in sustained,

multi-log(10) IU/mL reductions in HCV RNA in upper dose cohorts. These results

support further clinical evaluation of danoprevir in patients with chronic HCV.

. Published by Elsevier B.V.

PMID: 21145848 [PubMed - as supplied by publisher]

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...